Jesse J. Cureton
About Jesse J. Cureton
Independent director of HomeTrust Bancshares, Inc. (HTB); age 64; director since 2024 with current term expiring in 2026. Background includes senior operating and customer-experience leadership in healthcare and banking, notably as former EVP & Chief Consumer Officer at Novant Health and prior 25-year career at Bank of America/U.S. Trust; executive education at Harvard Business School (value measurement in healthcare) and Wharton (investments). Joined HTB’s Board effective May 20, 2024 after serving as an advisory director since September 25, 2023 .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Novant Health | Executive Vice President & Chief Consumer Officer | Joined 2013; former role (end date not disclosed) | Led system-wide rebrand; omnichannel marketing; initiatives on price transparency, personalized experiences, health equity |
| Bank of America / U.S. Trust | Regional Executive & Managing Director; earlier roles up to Regional President | 25-year career (dates not individually disclosed) | Led local merger integration for U.S. Trust; advisor training; improved staff satisfaction, retention, productivity |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| UNC-Chapel Hill Board of Visitors | Past Chair | Not disclosed | Higher-education governance |
| Queens University of Charlotte | Chair-Elect, Board of Trustees | Not disclosed | Higher-education governance |
| Foundations for the Carolinas | Board service | Not disclosed | Community/arts/education focus |
| Charlotte Regional Business Alliance | Chair (2019) | 2019 | Regional economic development |
| Bechtler Museum of Modern Art | Board service | Not disclosed | Arts governance |
| Charlotte Center City Partners | Board service | Not disclosed | Community development |
No public company directorships disclosed; external roles are primarily non-profit/academic, reducing interlock/conflict risk .
Board Governance
- Independence: Determined “independent director” under NYSE standards; majority of Board (10/11) independent including Cureton .
- Committees:
- Audit Committee member (Chair: Laura C. Kendall; all members independent; Kendall and Switzer designated financial experts) .
- Compensation and Human Capital Committee member (Chair: Craig C. Koontz; all members independent) .
- Attendance: In FY2024, no incumbent director attended fewer than 75% of Board and assigned committee meetings; Board met eight times; Audit met 13x; Asset/Liability met 4x; Executive & Risk met 4x .
- Term/tenure: Director since 2024; current term expires 2026 .
Fixed Compensation
| Metric (FY2024) | Amount | Notes |
|---|---|---|
| Fees Earned or Paid in Cash | $38,417 | Includes annual retainer and meeting fees . |
| Stock Awards (grant-date fair value) | $33,629 | Annual restricted stock award . |
| Option Awards | $0 | No options granted . |
| Change in Pension/Deferred Comp Value | $0 | No Director Emeritus/above-market deferred interest . |
| All Other Compensation | $280 | Dividends on unvested restricted stock . |
| Total | $72,326 | FY2024 director compensation . |
Director compensation framework:
- Annual cash retainer $34,000; committee meeting fees $750 per meeting ≥60 minutes; targeted annual restricted stock award ≈$34,000; Chair/Lead $15,000; Audit Chair $10,000; Compensation Chair $7,500; Governance Chair $5,000 (FY2024) .
- Changes approved March 23, 2025: equity target increased to $40,000 (effective June 1, 2025); Audit Chair $12,000; Compensation Chair $9,000; Governance Chair $6,000; Chair $40,000; added Asset/Liability Chair $3,000; committee meeting fee threshold reduced to 30 minutes (from Jan 1, 2025) .
Performance Compensation
| Element | Structure | Metrics | Payout/Status |
|---|---|---|---|
| Director equity grant | Time-based restricted stock | None disclosed for directors (no performance conditions) | Annual grant; time-vest, not performance-vest . |
HTB does not disclose performance-based equity or cash incentives for non-employee directors; equity is time-based restricted stock .
Other Directorships & Interlocks
- Public company boards: None disclosed .
- Notable non-profit/academic boards: UNC Board of Visitors (Past Chair), Queens University Board of Trustees (Chair-Elect), Foundations for the Carolinas, Charlotte Regional Business Alliance (Chair 2019), Bechtler Museum, Charlotte Center City Partners .
- Potential interlocks: None identified with HTB competitors/suppliers/customers .
Expertise & Qualifications
- Technical/functional: Consumer experience leadership, marketing, public relations, community engagement; banking leadership including merger integration and advisor training .
- Education: Executive education programs at Harvard Business School (value measurement for healthcare) and Wharton Executive Education Institute (investments) .
- Board-relevant credentials: Service on Audit and Compensation committees supports oversight of financial reporting and pay practices; independent under NYSE standards .
Equity Ownership
| Holder | Shares Beneficially Owned | % of Class | Notes |
|---|---|---|---|
| Jesse J. Cureton, Jr. | 1,218 | 0.01% | As of March 20, 2025; includes shares held directly/indirectly per SEC methodology . |
| Unvested/Vesting | Quantity | Vesting Date | Plan |
|---|---|---|---|
| Unvested restricted stock | 1,218 | May 31, 2025 (full vest) | 2022 Omnibus Incentive Plan; annual director grant . |
Ownership alignment:
- Stock ownership guidelines: Non-employee directors must hold five times the annual Board retainer; 5-year compliance window; retention requirements if below threshold; as of Dec 31, 2024, all directors either satisfied or progressing toward minimum levels .
- Pledging/hedging: Insider trading policy in place; no pledging disclosed for Cureton .
- Options: None disclosed for Cureton .
Governance Assessment
- Board effectiveness: Committee memberships in Audit and Compensation place Cureton in core oversight lanes (financial reporting, internal controls, pay design); Audit Committee issued Report recommending inclusion of audited financials in 10-K, evidencing engagement .
- Independence and conflicts: Independent under NYSE; related-party transaction policy places oversight with Audit Committee; ordinary-course director/officer loans permitted on market terms; no Cureton-specific related-party transactions disclosed .
- Attendance/engagement: Board and committees met frequently in FY2024; no incumbent director fell below 75% attendance threshold; Cureton serves on two high-touch committees, indicating active engagement .
- Compensation alignment: Balanced mix of cash retainer, meeting fees, and time-based equity; modest absolute value; guideline requires 5x retainer alignment over five years; he currently holds 1,218 shares, with vesting scheduled in 2025, consistent with new-director progression .
- Shareholder signals: Say-on-pay advisory approval passed (11.48M for vs 0.36M against), indicating constructive investor sentiment toward compensation governance; auditor ratification strongly supported .
Red flags
- None disclosed specific to Cureton: no related-party transactions, no pledging, no option repricing, no tax gross-ups; director equity is time-based, not performance-metric based (typical for directors) .
Contextual notes
- Committee chair fee and equity grant target increases effective in 2025 reflect modest modernization of director comp; Cureton is not currently a chair, so direct impact is primarily equity grant target increase post-June 1, 2025 .
- Committee composition changes: Koontz retired May 19, 2025; future committee rosters may shift, but 2025 proxy shows Cureton on Audit and Compensation .
Appendix: Committee Memberships (current per 2025 proxy)
| Committee | Members | Chair | Cureton Member? |
|---|---|---|---|
| Audit | Kendall; Cureton; Hancock; Koontz; Switzer | Laura C. Kendall | Yes |
| Compensation & Human Capital | Koontz; Cureton; James; Lowe; Neelagaru; Williams | Craig C. Koontz | Yes |
| Asset/Liability | Switzer; Hancock; Jacobs; Neelagaru; Westbrook | John A. Switzer | No |
| Executive & Risk | Board executive/risk oversight (membership not fully enumerated here) | Not disclosed | Not disclosed |
| Governance & Nominating | Williams; James; Kendall; Lowe; Neelagaru | Richard T. Williams | No |
Director Retainer and Equity Grant Policy (FY2024 base; 2025 changes)
| Component | FY2024 Terms | 2025 Update |
|---|---|---|
| Annual cash retainer | $34,000 | Chair retainer to $40,000 (Jan 1, 2025) |
| Committee meeting fee | $750 per meeting ≥60 min | Threshold reduced to 30 min (Jan 1, 2025) |
| Board meeting fee (excess) | $1,500 per in-person Board meeting >10/year | No change disclosed |
| Chair retainers | Lead/Chair $15,000; Audit Chair $10,000; Comp Chair $7,500; Governance Chair $5,000 | Audit $12,000; Comp $9,000; Governance $6,000 (Mar 1, 2025); Asset/Liability Chair $3,000 added (Mar 1, 2025); M&A Chair per-meeting to $1,500 (Jan 1, 2025) |
| Annual equity grant (non-employee director) | Target ≈$34,000; granted around May 31; 2024 award: Cureton 1,218 RS; vest full on May 31, 2025 | Target to $40,000 effective June 1, 2025 |
Beneficial Ownership Table (As of March 20, 2025)
| Name | Shares | % of Class |
|---|---|---|
| Jesse J. Cureton, Jr. | 1,218 | 0.01% |
Say-on-Pay and Shareholder Voting (May 19, 2025 Annual Meeting)
- Say-on-pay advisory vote: For 11,482,701; Against 357,695; Abstain 101,541; Broker non-votes 3,256,228 — Approved .
- Auditor ratification (Crowe LLP FY2025): For 15,073,426; Against 13,400; Abstain 111,339 — Approved .
- Director elections (Kendall; Lowe; Neelagaru): All elected by plurality; detailed votes disclosed .